Evaluation of the Effect of Narrowband UVB Versus Methotrexate on Serum TWEAK Level in Psoriasis

NCT ID: NCT04811911

Last Updated: 2021-03-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-12-13

Study Completion Date

2021-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to evaluate the effect of NB-UVB versus MTX on serum TWEAK level in psoriatic patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Narrowband ultraviolet B

Patients will receive 8 sessions of NB-UVB per month for 3 successive months

Group Type ACTIVE_COMPARATOR

Narrowband ultraviolet B

Intervention Type RADIATION

Patients will receive 8 sessions of NB-UVB per month for 3 successive months

Methotrexate group

Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months

Group Type ACTIVE_COMPARATOR

Methotrexate

Intervention Type DRUG

Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months

healthy individuals as control group

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Narrowband ultraviolet B

Patients will receive 8 sessions of NB-UVB per month for 3 successive months

Intervention Type RADIATION

Methotrexate

Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NB-UVB MTX

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with moderate to severe plaque psoriasis of any age and gender.

Exclusion Criteria

* History of psoriasis treatment with systemic and biological agents prior to the study for at least 3 months.
* Pregnancy and lactation.
* Infections
* Patients with chronic diseases: hepatic disorders, hematologic disease, chronic renal failure or cancer
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aswan University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

El Hassan Mohsen Mansour Mahmoud

Principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Moustafa A El Taieb, Professor

Role: STUDY_CHAIR

Faculty of medicine aswan university

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aswan University - Faculty of Medicine

Aswān, Aswan Governorate, Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

498/12/20

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effect Narrow-Band UVB Radiations
NCT05647187 COMPLETED NA
Excimer Light in Psoriasis
NCT05283876 COMPLETED NA
Nicotinamide in the Treatment of Psoriasis
NCT01763424 COMPLETED PHASE2/PHASE3